Minireview: Prospect of Doxycycline in Systemic Lupus Erythematosus Treatment

dc.contributor.author	Indriyanti, Niken
dc.contributor.author	Soeroso, Joewono
dc.date.accessioned	2019-11-05T15:57:54Z
dc.date.available	2019-11-05T15:57:54Z
dc.date.issued	2019
dc.identifier.issn	2407-6090
dc.identifier.uri	http://repository.unmul.ac.id/handle/123456789/1875
dc.description.abstract	Doxycycline has non-antibiotic effects which are necessary for lupus treatment, such as immunosuppressive, anti-inflammatory, and anti-depressive effects. This widely used drug is a promising one to be developed as lupus drug since doxycycline has no data of its microbial resistance and it is safe for maternity. The other benefit is that doxycycline has lower side effects than the current drugs for lupus treatment. It gives excellent chances for women with lupus to be pregnant and have healthy babies. This article contains the compilation data of doxycycline target sites beyond its beneficial activities for lupus and also its limitations. Finally, this data will be a background for doxycycline in lupus drug development.
dc.publisher	Journal of Tropical Pharmacy and Chemistry
dc.title	Minireview: Prospect of Doxycycline in Systemic Lupus Erythematosus Treatment